中国精神分裂症的全基因组关联分析及其转化医学进展  

Progress of GWAS and Translational Medicine for Schizophrenia in China

作　　者：李胜[1] 张爱萍[1] 贺林[1,2] 

机构地区：[1]上海交通大学Bio-X研究院,上海交通大学遗传发育与精神神经疾病教育部重点实验室,上海200030 [2]复旦大学生物医学研究院,上海200032

出　　处：《中国科学：生命科学》2013年第1期31-38,共8页Scientia Sinica(Vitae)

基　　金：国家"十二五"科技支撑计划(批准号:2012BAI01B09;2012AA021802);国家重点基础研究发展计划(批准号:2010CB529600)项目资助

摘　　要：我国在精神分裂症的遗传学和生命组学研究方面取得了很大进展,如在全基因组关联分析(genome-wide association study,GWAS)方面工作获得了一系列成果.随着我国对重大疾病转化医学的逐步关注和重视,利用在精神分裂症上已经获得的广泛和深入的研究结果,寻找精神分裂症各种临床应用的生物标记物研究,系统性地建立适合于类似精神分裂症这类复杂疾病的早期诊断、干预和预防的临床咨询和应用体系等将是该疾病转化医学方面可实施的方法和案例.精神分裂症的转化医学方面还涉及精神分裂症患者的个体化用药方案建立.药物疗效和药物不良反应的个体差异具有较复杂的环境和遗传背景,结合精神分裂症的遗传学病因和药物作用的遗传学差异,将有效发挥治疗药物的功效,并降低重大不良反应在敏感个体上的发生.对精神分裂症这类给国家和社会带来极其重大负担的重大疾病,积极推动我国在此类疾病上的基础研究成果转化和转化医学的实施具有重要的社会效应和积极的带动作用.Much progress has been made in the field of genetics and genomics research for schizophrenia in China, such as genome-wide association study （GWAS）. Translational medicine for major diseases has been paid increasing attention in China. How to establish an appliction system of clinical consulation and clinical practices for earlier diagnosis, intervention and prevention, based on clinical biomarkers found by morden research, will be possible methods and cases for translational research for major diseases, especially for schizophrenia. Translational medicine for schizophernia could also include individualized drug using for patients. Individual differences of drug effects and adverse reactions are related to complicated environmental and genetic backgrounds. While we concern the genetic differences for disease pathological mechanism and drug effects, drug＇s therapeutical effects could be increased, and major drug adverse reactions on sensitive individuals are decreased. In China, translating basic research results to translational medicine practices for major diseases including schizophrenia, which has been a big burden to our country, will bring social concerns and provide a leading example.

关 键 词：精神分裂症 全基因组关联分析 转化医学 

分 类 号：R749.3[医药卫生—神经病学与精神病学]